Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A ~~stentless~~ suture comprising PTFE and ~~having~~ a polymer ~~coating~~ containing releasable biological agents for the reduction of intimal hyperplasia, smooth muscle cell proliferation in a sutured, grafted, or injured area of a vessel or arterial wall.

Claim 2 (currently amended): The ~~stentless~~ suture in accordance with claim 1, wherein said polymer ~~coating~~ is a plasma-assisted coating deposited upon the suture.

Claim 3 (currently amended): The ~~stentless~~ suture in accordance with claim 1, wherein said biological agents are selected from a group of substances consisting of: rapamycin, taxol, derivatives of taxol and rapamycin, and combinations thereof.

Claim 4 (previously presented): A suture comprising PTFE having a reservoir containing releasable biological agents for the reduction of intimal hyperplasia, smooth muscle cell proliferation in a sutured, grafted area or injured area of a vessel or arterial wall, said biological agent being osmotically released through the pores in the reservoir.

Claim 5 (previously presented): The suture in accordance with claim 4, wherein said biological agents are selected from a group of substances consisting of: rapamycin, taxol, derivatives of taxol and rapamycin, and combinations thereof.

Claim 6 (previously presented): The suture in accordance with claim 4, wherein said biological agents have means for timed release from the suture reservoir.

Claim 7 (new): The suture in accordance with claim 1, wherein said PTFE has a predetermined density and thickness providing means for controlling timed release of said biological agents.

Claim 8 (new): The suture in accordance with claim 1, wherein said PTFE and said polymer each has a predetermined respective radius.

Claim 9 (new): A medical device comprising PTFE and a polymer containing releasable biological agents for the reduction of intimal hyperplasia and smooth muscle cell proliferation in a sutured, grafted, or injured area of a vessel or arterial wall.

Claim 10 (new): The medical device in accordance with claim 9, wherein said polymer is a plasma-assisted coating deposited upon the medical device.

Claim 11 (new): The medical device in accordance with claim 9, wherein said biological agents are selected from a group of substances consisting of: rapamycin, taxol, derivatives of taxol and rapamycin, and combinations thereof.

Claim 12 (new): A medical device comprising PTFE having a reservoir containing releasable biological agents for the reduction of intimal hyperplasia and smooth muscle cell proliferation in a sutured, grafted area or injured area of a vessel or arterial wall, said biological agents, being osmotically released through pores in a reservoir.

Claim 13 (new): The medical device in accordance with claim 12, wherein said biological agents are selected from a group of substances consisting of: rapamycin, taxol, derivatives of taxol and rapamycin, and combinations thereof.

Claim 14 (new): The medical device in accordance with claim 12, wherein said biological agents have means for timed release from the suture reservoir.

Claim 15 (new): The medical device in accordance with claim 9, wherein said PTFE has a predetermined density and thickness providing means for controlling timed release of said biological agents.

Claim 16 (new): The suture in accordance with claim 9, wherein said PTFE and said polymer each has a predetermined respective radius.